SCHEMBL4325871

SCHEMBL4325871

O=C(NCc1ccccn1)c1nc(-c2cccnc2)n2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 2/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 2/20 0.46
NTRK1 P04629 3/20 0.45
NTRK3 Q16288 2/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 5/20 0.44
ADORA2A P29274 4/20 0.44
ADORA2B P29275 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4327243 0.86 ALDH1A1 (0.55) RAB9ALMNAPOLBTSHRHTT
SCHEMBL4327641 0.86 IDH1 (0.43) LMNANTRK1KDM4EMAPTALDH1A1
SCHEMBL4323392 0.85 GLS (0.43) MAPTKMT2AMEN1
SCHEMBL4319159 0.84 ADORA2A (0.45) RAB9ALMNAPOLBHSD17B10ADORA2A
SCHEMBL4332986 0.84 RAB9A (0.47) RAB9ALMNANPC1POLBTSHR
SCHEMBL4327554 0.82 ATR (0.57) RAB9ANPC1POLBTSHRADORA2A
SCHEMBL4326314 0.82 HTT (0.47) RAB9ANPC1POLBTSHRHTT
SCHEMBL4331382 0.82 ADORA2A (0.46) RAB9APOLBHTTHSD17B10ADORA2A
SCHEMBL4329714 0.78 ATR (0.53) RAB9ALMNANPC1POLBTSHR
SCHEMBL13578316 0.77 ATR (0.58) LMNAPOLBALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 RAB9A 1558/4885LMNA 4260/4885NPC1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.